Telix Pharmaceuticals

Fishers,  IN 
United States
http://www.telixpharma.com

• Booth: 408

Telix is a global, commercial-stage biopharmaceutical company focused on the development of diagnostic and therapeutic (‘theranostic’) products using targeted radiation. Our products use targeted radiation to image disease and deliver truly personalized therapy in areas of significant unmet medical need. Telix’s theranostic pipeline aims to address significant unmet medical need in prostate, kidney, brain, and blood cancers, and a range of rare diseases.

Brands: Illuccix

 Press Releases

• New Prostate Cancer Imaging Agent Gozellix (Mar 21, 2025)
  Telix today announces that the United States (U.S.) Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Gozellix® (TLX007-CDx, kit for the preparation of gallium-68 (⁶⁸Ga) gozetotide injection), Telix’s next-generation PSMA-PET imaging agent for prostate cancer.  Gozellix®, after radiolabeling with ⁶⁸Ga, is indicated for PET scanning of PSMA positive lesions in men with prostate cancer who have suspected metastasis and are candidates for initial definitive therapy, and those with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.  
  Read the full ASX release here.